-
BeiGene's Q1 2025 Financial report
Market Trend
BeiGene's Q1 2025 report highlights a 50.2% revenue growth, with zanubrutinib sales exceeding 5 billion RMB and achieving its first quarterly profit under US GAAP. The company also advances its oncology pipeline globally.
-
-
-
Pfizer's Q1 2025 Financial report
Market Trend
Pfizer's Q1 2025 earnings report highlights strong adjusted EPS growth despite revenue decline. Key drivers include Comirnaty and Vyndaqel, with cost savings and R&D efficiency boosting performance.
-
Eli Lilly's Q1 2025 Financial report
Market Trend
Eli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
-
-
Novartis's Q1 2025 Financial report
Market Trend
Novartis reports strong Q1 2025 results with 12% sales growth, 27% core operating income increase, major FDA approvals, and raised full-year guidance amid robust innovation and strategic execution.
-
-
WuXi AppTec's Q1 2025 Financial report
Market Trend
WuXi AppTec reports strong Q1 2025 results with net profit up 89% YoY and orders reaching RMB 52.33 billion. Its CRDMO model drives growth across chemistry, testing, and biology services, showing resilience amid global challenges.
-
大荔县|
广宁县|
桃园县|
南岸区|
西昌市|
黄大仙区|
米泉市|
延寿县|
教育|
壶关县|
普兰县|
安多县|
于都县|
江西省|
永安市|
邳州市|
墨脱县|
福泉市|
崇明县|
临城县|
桃江县|
永定县|
古浪县|
汝南县|
基隆市|
华容县|
特克斯县|
大理市|
无为县|
太保市|
安图县|
商南县|
新绛县|
潞西市|
乌鲁木齐县|
桂林市|
曲阳县|
奈曼旗|
龙山县|
金阳县|
承德市|